Single dose acute toxicity testing for N,N-bis(2-mercaptoethyl)-N',N' diethylethylenediamine in beagles

Regul Toxicol Pharmacol. 2014 Jul;69(2):217-25. doi: 10.1016/j.yrtph.2014.04.001. Epub 2014 Apr 8.

Abstract

N,N-Bis(2-mercaptoethyl)-N',N'-diethylenediamine (BMEDA) is used in the preparation of the (188)Re-BMEDA-liposome as a chelator to deliver rhenium 188 into liposomes. Although the safety of the (188)Re-BMEDA-liposome had been established, the use of BMEDA in preparing the liposome is of interest; however, an assessment of its safety is warranted. In this present work, we report on the acute toxicity study of BMEDA in beagles to identify doses causing no adverse effect and doses causing life-threatening toxicity. In a single dose 14-day systemic toxicity study conducted in beagles, BMEDA was without compound-related adverse effects at doses of up to 2mg/kg in a series of clinical observations and clinical pathology examinations. The results of these studies could aid in choosing doses for repeat-dose studies and in the selection of starting doses for Phase 1 human studies.

Keywords: Acute toxicity; N,N-Bis(2-mercaptoethyl)-N′,N′-diethylenediamine; The (188)Re-liposome.

MeSH terms

  • Animals
  • Dogs
  • Dose-Response Relationship, Drug
  • Ethylenediamines / administration & dosage*
  • Ethylenediamines / toxicity*
  • Female
  • Injections, Intravenous
  • Liposomes
  • Male
  • Organometallic Compounds / administration & dosage*
  • Organometallic Compounds / toxicity*
  • Radioisotopes / administration & dosage
  • Rhenium / administration & dosage
  • Toxicity Tests, Acute*

Substances

  • 188Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine
  • Ethylenediamines
  • Liposomes
  • Organometallic Compounds
  • Radioisotopes
  • Rhenium